Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$49.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Syneron Medical Ltd receives US FDA clearance to market the ultrashape system for fat cell destruction


Monday, 14 Apr 2014 09:00am EDT 

Syneron Medical Ltd:Receives the United States Food and Drug Administration (FDA) clearance to market the UltraShape System for non-invasive reduction of abdominal circumference via fat cell destruction.UltraShape System is the first and only non-invasive body shaping treatment that uses pulsed focused ultrasound energy that precisely targets subcutaneous fat, while keeping the surrounding tissue, vasculature, nerves and muscles intact. 

Company Quote

11.8
0.24 +2.08%
27 Feb 2015